Last updated: March 2026
BPC-157 is a 15-amino acid peptide with over 544 published animal studies showing tissue repair, anti-inflammatory, and gut-healing effects. It remains a research compound without FDA approval, but has one of the most extensive preclinical safety profiles of any investigational peptide.
A visual breakdown of 30+ years of research on the most talked-about healing peptide
Background
A naturally occurring peptide with a 30-year research history — here's what it actually is, how it works, and how it's administered.
A 15-amino-acid peptide (pentadecapeptide) naturally found in human gastric juice. First described in 1993 by Dr. Predrag Sikiric. Full name: Body Protection Compound-157.
Activates VEGFR2 and nitric oxide signaling (Akt-eNOS pathway). Modulates angiogenesis — promotes new blood vessel growth in injured tissue while inhibiting VEGF-driven MAPK signaling in tumor cell lines (Radeljak 2004). Reduces inflammatory cytokines, enhances growth hormone receptor expression, and activates ERK1/2 signaling for cell repair.
Half-life: less than 30 minutes. Metabolized in liver. Cleared by kidneys. Routes studied: injection (subcutaneous, intramuscular, intraperitoneal, intraarticular), oral, and topical.
Mechanism of Action
BPC-157 doesn't work through a single pathway — researchers have identified at least four distinct biological mechanisms active across tissue types.
Enhances VEGFR2 activity and NO production. Creates new capillaries in damaged tissue. Particularly beneficial in poorly vascularized tissues like tendons — which heal slowly precisely because they have limited blood supply.
Reduces pro-inflammatory cytokines. Upregulates cytoprotective factors including heme oxygenase-1 (HO-1). Reduces oxidative stress and prevents mitochondrial dysfunction — protecting cells from secondary damage during healing.
Stabilizes acetylcholine receptors at the neuromuscular junction. Reverses paralysis from neuromuscular blockers in animal models. Restores glutamatergic signaling — a pathway relevant to both peripheral nerve function and CNS recovery.
Activates ERK1/2 signaling pathway. Enhances endothelial cell proliferation and migration. Promotes collagen formation and extracellular matrix development — the structural scaffolding required for functional tissue regeneration.
Preclinical Evidence
BPC-157 showed positive results across a wide range of musculoskeletal injuries in animal models. Bar size represents number of positive studies per tissue type.
ALL data below is preclinical (animal research). These results come from studies in rats, mice, and rabbits — not humans. Animal results do not automatically translate to human outcomes. This data demonstrates biological plausibility and guides further research, not clinical effectiveness in people.
Human Evidence
Thirty years of compelling animal research. Three tiny pilot studies in humans. Here's what we actually know about BPC-157 in people.
Intraarticular injection for chronic knee pain. 7 of 12 patients (58%) reported pain relief lasting >6 months after a single injection. Retrospective design — no control group, limited conclusions.
Small pilot study examining BPC-157 for bladder inflammation. Extremely limited sample size, early-stage exploratory research only.
Safety and dosing study examining intravenous administration. No adverse effects reported. Primarily established initial safety signals — not efficacy data.
BPC-157 research began in 1993. In 30+ years, the field has produced 544 identified studies — the vast majority in rodents. Zero randomized controlled trials in humans exist. This is an extraordinary gap between preclinical promise and clinical validation. The peptide may work exactly as claimed, or animal results may not translate. We genuinely do not know.
Origins of Research
BPC-157 was originally isolated from gastric juice and first studied for gastrointestinal healing — this remains its most evidence-backed application area.
Counteracted gastric damage from NSAIDs (ibuprofen, aspirin) in animal models. May protect stomach lining from medication-induced ulceration.
Healed cysteamine-induced colitis. Promoted intestinal anastomosis healing. In clinical trials as PL-14736 for IBD (Pliva, Croatia) — the only human pharmaceutical program for BPC-157.
Healed colocutaneous fistulas via nitric oxide system modulation. Fistulas are notoriously difficult to treat — this represents a potentially high-value application.
Reversed short bowel syndrome in animal models. Enhanced intestinal adaptation and mucosal regrowth following extensive bowel resection.
Enhanced mucosal integrity and barrier function. Reduced intestinal permeability in animal models — though "leaky gut" remains a contested clinical concept.
Legal & Regulatory
BPC-157's status varies dramatically by context — from research chemical to explicitly banned substance. Know where you stand.
| Organization | Status | Year |
|---|---|---|
| FDA | ⚠ Category 2 Bulk drug substance — safety concerns; cannot be compounded | 2023 |
| WADA | ✕ Banned Specifically named on prohibited list | 2022 |
| UFC | ✕ Banned Specifically banned | 2022 |
| NFL | ✕ Banned Specifically banned | 2022 |
| NBA | ◆ Covered Non-specific PED ban covers peptide hormones | — |
| NHL | ◆ Covered Non-specific PED ban | 2013 |
| MLB | ◆ Covered Peptide hormone ban | 2019 |
| NCAA | ◆ Covered Peptide hormone ban | 1999 |
Breaking Research (2024-2025)
After decades of animal-only research, the first human pharmacokinetic and safety data emerged in 2024-2025. Here's what we learned.
Two healthy adults received IV doses up to 20mg — making this the first study to characterize BPC-157 pharmacokinetics in human blood. Results: well tolerated, no adverse events, no clinically meaningful changes in vitals, ECGs, or lab work. Plasma concentrations were dose-proportional and cleared within 24 hours.
The American Journal of Sports Medicine analyzed 544 articles spanning 1993-2024, including 36 studies (35 preclinical, 1 clinical). Conclusion: BPC-157 "could help heal musculoskeletal injuries." Notably, no harmful effects were observed in any animal study. Concerns centered on unregulated production and the need for more clinical safety data.
A pilot study examined 12 women with severe interstitial cystitis who received 10mg BPC-157 injected directly into the bladder wall. This represents one of the first targeted human applications beyond musculoskeletal tissue.
In a retrospective review of 12 patients with chronic knee pain who received single intraarticular injections, 7 patients (58%) reported pain relief lasting more than 6 months. Small sample, no control group — but suggestive of durable effects.
2025 ACG Journal Review — Oral BPC-157: The American College of Gastroenterology's journal described oral BPC-157 as an "emerging adjunct" in gastroenterology. Key findings: protective against NSAID-induced gastropathy, promotes mucosal healing, and modulates the gut-brain axis. Notably, this appeared in a mainstream GI journal — not a niche peptide publication.
Animal Toxicology Summary: Across mice, rats, rabbits, and dogs, researchers tested doses ranging from 6 mcg/kg to 20 mg/kg. No toxic or lethal dose was established — researchers simply couldn't find one. No genetic, embryo-fetal, or organ toxicity was observed in any study.
Protocol Data
The healing peptide stack most commonly discussed in the research community. Different mechanisms, complementary timing.
Why the combination? BPC-157 works locally (targets injury site) and has a ~4-hour half-life. TB-500 works systemically (distributes throughout body) with a longer half-life. The stack targets different healing pathways — BPC-157 for localized tissue repair and gut healing, TB-500 for systemic inflammation and deeper tissue regeneration.
| Phase | BPC-157 | TB-500 | Route |
|---|---|---|---|
| Loading (Weeks 1-2) | 250-500 mcg twice daily | 750 mcg twice weekly | SubQ (near injury or abdomen) |
| Maintenance (Weeks 3-6) | 250 mcg once daily | 750 mcg once weekly | SubQ |
A full 6-week BPC-157 + TB-500 cycle typically runs $150-350 from research peptide suppliers. BPC-157 is the larger cost driver due to twice-daily dosing during loading phase. Quality and purity vary significantly between sources.
Weeks 1-2: Reduced pain and inflammation, early healing cascade. Weeks 3-4: Improved range of motion, functional gains. Weeks 5-6: Significant resolution of symptoms in most cases. Chronic injuries may need a second cycle after 2-4 weeks off.
Oral BPC-157 for Gut Health: For gut-specific applications, oral administration is commonly used at 250-500 mcg on an empty stomach, once or twice daily. Can be taken sublingually (under the tongue) or in capsule form. The peptide is uniquely stable in gastric acid — unlike most peptides that are destroyed by digestive enzymes.
Safety Data
A tale of two datasets: one remarkably clean preclinical record — and one enormous gap in human safety data.
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Bottom Line
Separating what the peer-reviewed evidence confirms from what we genuinely don't know yet.
Source Material
All data on this page is sourced from published peer-reviewed systematic reviews. Full citations below.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
Continue Reading
Dosing guides, delivery methods, and safety information for BPC-157 and related peptides.
More Research
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Everything you need for peptide preparation and administration
Affiliate links help support MeetPeptide at no extra cost to you.
Based on animal model research (30+ years, 544+ studies) and the known biological mechanisms of BPC-157. No controlled human trials have been completed — these timeframes are extrapolated from preclinical data and anecdotal reports. Results are not guaranteed.
BPC-157 begins upregulating vascular endothelial growth factor (VEGF) and nitric oxide (NO) production within days of administration — mechanisms confirmed in multiple animal studies (Sikiric et al.). This triggers angiogenesis (new blood vessel formation) in damaged tissue. Inflammation markers in injured areas begin declining as COX-2 inhibition and free radical scavenging activity increase. Early pain reduction is often the first subjective change users report, consistent with the anti-inflammatory mechanisms observed in rodent injury models.
Animal studies show active collagen synthesis and fibroblast proliferation in injured tendons and ligaments within 2–4 weeks of BPC-157 administration. The new blood vessels formed through VEGF upregulation begin supplying oxygen and nutrients to previously hypovascular tissue (tendons heal slowly in part because of limited blood supply). Studies in rodent models of Achilles tendon and rotator cuff injuries (Pevec et al., 2010; Staresinic et al.) show significantly accelerated functional recovery compared to controls at the 4-week mark.
At 3 months, animal models show near-complete or complete structural repair of moderate tendon and ligament injuries with BPC-157 treatment — versus incomplete healing in controls. Studies also demonstrate significant recovery of crush-injured muscle (Novinscak et al.), nerve repair (Gjurasin et al., 2010), and gut lining restoration in models of IBD and NSAID-induced damage. The broad tissue-protective effects across injury types point to BPC-157's role in activating systemic healing pathways rather than targeting specific tissues.
Extended animal studies suggest ongoing tissue remodeling and structural improvement beyond the acute healing phase. Studies in bone fracture models show significantly improved bone density and callus formation at 6+ weeks (scaled to human timelines, this represents months). Long-term organ protection effects (gastric, hepatic, cardiac) have been documented in chronic stress and toxin exposure models. Important caveat: No long-term human trial data exists. The 2025 systematic reviews (OJSM 2025, PMC12313605) confirm efficacy evidence in animals is strong, but acknowledge the absence of completed human clinical trials means long-term human safety and efficacy remain unconfirmed.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice. BPC-157 is not approved by the FDA for any medical use. It is classified as a Category 2 bulk drug substance and cannot be legally compounded by pharmacies. Always consult with a qualified healthcare provider before starting any supplement or peptide protocol. Data sourced from published peer-reviewed systematic reviews (Orthopaedic Journal of Sports Medicine 2025, PMC12313605; PMC12446177, 2025).
⚕️ Always consult a healthcare provider before starting any peptide protocol.
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protective protein found in human gastric juice. It is a research compound with extensive animal study data showing tissue repair, anti-inflammatory, and gut-healing properties. It is not FDA-approved and is currently classified as a research chemical in the United States.
BPC-157 has shown a favorable safety profile in animal studies and limited human anecdotal reports, with no significant toxicity observed even at high doses in rodent models. However, no large-scale human clinical trials have been completed as of 2026, which means the full human safety profile is unknown. It is generally considered relatively safe for research use but is not FDA-approved and quality/purity varies significantly between sources.
BPC-157 has demonstrated multiple mechanisms of action in preclinical research: it accelerates healing of tendons, ligaments, muscles, and gut tissue; reduces inflammation via nitric oxide pathway modulation; promotes angiogenesis (new blood vessel formation); and protects the gastric lining. Animal studies show benefits for gut inflammation (IBD, leaky gut), sports injuries, and neurological function. Human data remains limited to case reports and small studies.
BPC-157 can be administered subcutaneously (under the skin), intramuscularly, or orally. For systemic effects, subcutaneous injection near the injury site at doses of 200–500mcg per day is the most commonly reported research protocol. For gut-specific applications, oral administration (encapsulated or dissolved in water) has shown efficacy in animal models. There is no established human dosing protocol — all usage is off-label and for research purposes only.
In the United States, BPC-157 exists in a regulatory grey area. It is not FDA-approved as a drug and is not a controlled substance, but the FDA has included it on a list of compounds that compounding pharmacies cannot legally compound for human use (as of 2024). It can legally be purchased as a research chemical for non-human use. In most other countries it is similarly unscheduled but not approved for human use. Legal status varies by country.